Compare Crispr Therapeutics AG (CRSP) vs Prudential Financial Inc (PRU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Prudential Financial Inc — how do they compare? Crispr Therapeutics AG trades at $53.39 (market cap $4.88B), while Prudential Financial Inc trades at $113.09 (market cap $39.17B). The key difference: Prudential Financial Inc is far larger — about 8× Crispr Therapeutics AG's market cap, and Prudential Financial Inc pays a 4.93% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Prudential Financial Inc for 145 Days on average.
| CRSP | PRU | |
|---|---|---|
Market Cap | $4.88B | $39.17B |
Volume | 2,861,747 | 1,436,917 |
Sector | Health | Financials |
52-Week High | $74.92 | $125.13 |
52-Week Low | $44.34 | $92.00 |
Typical Hold Time | 77 Days | 145 Days |
Enterprise Value | $3.30B | $67.95B |
Dividend Yield | — | 4.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.39, up 1.99% on the day, but remains in a bearish technical trend. The company shows no revenue in 2025, with significant losses (net income margin -4,101.26%) and negative cash flow from operations. However, analyst sentiment is positive with a 57.9% buy rating and a $67.83 consensus price target, citing upcoming clinical data catalysts for its gene-editing therapies like CASGEVY and zugo-cel.
The outlook hinges on successful clinical execution and commercialization of its pipeline. Near-term catalysts include data readouts in autoimmune diseases, but high cash burn, intense competition, and regulatory risks pose substantial challenges. The stock offers high-risk, high-reward potential for investors betting on gene-editing breakthroughs.
Prudential Financial (PRU) trades at $113.09, up 0.65% with bearish technical signals but attractive valuation metrics including a P/E of 10.29 and P/S of 0.61. Recent earnings show mixed results with Q1 and Q2 2026 beats but a Q4 2025 miss. The company is executing a strategic overhaul including $3 billion capital rotation and $750 million cost savings while exiting emerging markets through the $185 million Alexforbes sale. Cash flow trends show strong operational performance with $6.3 billion from operations in 2025.
PRU presents a value opportunity with below-market valuations and dividend yield support, though technical weakness and mixed analyst sentiment warrant caution. The strategic refocus on core insurance and wealth management businesses positions the company for improved capital efficiency, while higher interest rates benefit investment income. Key risks include execution challenges in the restructuring and competitive pressures in the insurance sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Prudential Financial Inc
Prudential Financial is a large, diversified insurance company offering annuities, life insurance, retirement plan services, and asset management products. While it operates in a number of countries, the vast majority of revenue is generated in the United States and Japan. The company's investment management business, PGIM, contributes approximately 15% of its earnings and has over $1.5 trillion in assets under management. The U.S. businesses are responsible for about 45% of earnings and can be classified into Institutional Retirement Strategies, Individual Retirement Strategies, Group Insurance, Individual Life Insurance, and Assurance IQ. Finally, the international business segment of the company contributes approximately 40% of earnings with a strong market position in Japan.
Read more on PRU →
